Evotec SE stock (DE0005664809): after Nasdaq exit, investors focus on Q1 2025 update and strategy reset

After the Nasdaq delisting, Evotec SE remains listed in Frankfurt. Investors now look to the Q1 2025 update and the updated strategy as key catalysts for the biotech stock’s next phase.

Evotec SE has remained in focus with international investors after its American Depositary Shares were delisted from Nasdaq in 2024, while the primary listing on Xetra in Frankfurt continues to provide liquidity for the biotech stock. Market participants now look ahead to the company’s Q1 2025 update and strategy communication as the next catalysts, according to an overview published on May 15, 2025 by ad-hoc-news.de as of 05/15/2025. On May 21, 2026 the share traded around 4.92 EUR on Xetra after gaining roughly 6% on the day, according to price data from finanzen.net as of 05/21/2026.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec SE
• Sector/industry: Biotechnology, drug discovery services
• Headquarters/country: Hamburg, Germany
• Core markets: Europe and North America with a strong US customer base
• Key revenue drivers: Drug discovery and development partnerships, milestone and royalty agreements
• Home exchange/listing venue: Xetra (ticker: EVT)
• Trading currency: Euro (EUR)

Evotec SE: core business model

Evotec positions itself as a global research and development partner for pharmaceutical and biotechnology companies, with a focus on early-stage drug discovery as well as selected development services. The group combines biology, chemistry and data science platforms to support partners from target identification through preclinical development, according to the company’s profile on its website and recent investor materials published in 2024 by Evotec SE.

The business model is primarily based on fee-for-service contracts in research and development, complemented by milestone and potential royalty payments when partnered projects advance through clinical stages or reach the market. This mix of relatively stable service revenues and more volatile success-based payments is typical for contract research organizations with a strong innovation focus in the life-sciences sector.

Evotec reports its activities across multiple therapeutic areas, including neurology, metabolic diseases and oncology, and collaborates with both large pharmaceutical groups and smaller biotech companies. The company emphasizes its proprietary technology platforms, such as integrated high-throughput screening and biomarker expertise, as key differentiators that allow it to address complex biological questions for its partners, based on descriptions in corporate publications released in 2024 by Evotec SE.

Main revenue and product drivers for Evotec SE

The main revenue drivers for Evotec are long-term discovery and development alliances with major pharmaceutical and biotech clients, which provide recurring service income. These collaborations often include multi-year frameworks under which Evotec receives research funding in exchange for delivering discovery programs, according to business descriptions in company presentations published in 2024 by Evotec SE. In addition, Evotec can earn milestone payments when specific development steps are achieved.

Beyond fee-based research, Evotec also invests in selected co-owned pipelines where it shares the development risk with partners. In such models, the company typically contributes platform know-how and early research capabilities, while partners may take over later-stage clinical development. If successful, these programs may generate royalties on future product sales, introducing an element of long-term upside that is closely monitored by equity investors, as noted in background reports on the stock by MarketBeat updated in 2025 and accessible via MarketBeat as of 03/10/2025.

For the medium term, Evotec’s ability to scale its laboratory capacity and maintain high utilization rates in key locations such as Germany, the United Kingdom and North America is important for revenue growth. The company has highlighted investments in biologics manufacturing and cell and gene therapy services as additional growth areas that can broaden its revenue base, according to strategy communications released in 2024 by Evotec SE.

Conclusion

Evotec SE remains a notable player in the European biotech and contract research landscape, even after the Nasdaq delisting shifted investor focus back to its Frankfurt listing. The combination of recurring service revenues, potential milestone and royalty income and an expanded presence in the US through research sites and client relationships underpins the company’s strategic positioning. At the same time, investors are watching the Q1 2025 update and ongoing strategy execution closely, as these will help clarify the growth trajectory and risk profile of the stock in a competitive and innovation-driven industry environment.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.